Cellino Biotech, Inc.

Cellino Biotech, Inc. is a privately held biotechnology company focused on making personalized, autologous cell therapies accessible to patients. Headquartered in Cambridge, Massachusetts, the company's mission is to drive a healthspan renaissance by developing an autonomous biomanufacturing technology for cell, tissue, and organ replacement therapies.

Cellino's core offering is its proprietary NEBULA system, an AI-guided biomanufacturing platform that integrates image-guided machine learning, single-cell laser processing, and robotics. This technology is designed to automate the production of induced pluripotent stem cells (iPSCs) at scale, addressing the challenges of manual handling, variability, and high costs associated with current cell therapy manufacturing. The company aims to provide regenerative treatments for a range of degenerative diseases, including Parkinson's, diabetes, heart disease, and spinal cord injury.

Co-founded by Nabiha Saklayen (CEO), Matthias Wagner (CTO), and Marinna Madrid (Chief Product and Regulatory Officer), Cellino has raised a total of $125 million in funding, including an $80 million Series A led by Leaps by Bayer and a $25 million award from the Advanced Research Projects Agency for Health (ARPA-H). Recent milestones include securing FDA Advanced Manufacturing Technology designation in May 2025, deploying its first hospital-based iPSC foundry at Mass General Brigham, and being named to Fast Company's Annual List of the World's Most Innovative Companies of 2026. The company also partnered with Polyphron in January 2026 to advance scalable personalized tissue replacements.